TICKERNERD
Menu
CUECUEHealthcare · Biotechnology

CUE Stock Forecast: Cue Biopharma, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$23
−3.34% on the day

The 1 Wall Street analysts covering Cue Biopharma, Inc. hold a median 12-month price target of $115 — +396.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$174.2M
Ticker Nerd rank
47 / 100
Median analyst target
$115
Analysts covering
1
Revenue$5.7M+1250.6% y/y
Operating income−$5.4M
Net income−$5.2M
Free cash flow−$11.1M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.1%
1M
−27.8%
YTD
+153.3%
1Y
−6.5%
From 52W high
−37.0%
From 52W low
+336.5%
$5
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CUE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cue Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Size
70
Revisions
68
Value
56
Momentum
56
Growth
35
Quality
27
Issuance
10
Volatility
7

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (7): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26CUEHigh $115Median $115Low $115

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $115Median $115High $115

The green dot is the last close — the median target sits +396.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2025LUCID CAPITAL MARKETSInitiatesBuy$4.00
2 Apr 2025Citizens Capital MarketsReiteratesMarket Outperform—
20 Aug 2024StifelMaintainsBuy—
26 July 2024JMP SecuritiesMaintainsMarket Outperform—
26 July 2024Piper SandlerMaintainsOverweight—
9 Apr 2024OppenheimerMaintainsOutperform—
9 Apr 2024StifelMaintainsBuy—
3 Apr 2024Piper SandlerReiteratesOverweight—
13 Mar 2024JefferiesInitiatesBuy—
6 Nov 2023Piper SandlerMaintainsOverweight—
26 June 2023OppenheimerAssumesOutperform$10
15 June 2023StifelReiteratesBuy—
15 May 2023JMP SecuritiesReiteratesOutperform—
22 Mar 2023OppenheimerReiteratesOutperform—
22 Mar 2023StifelMaintainsBuy—
21 Nov 2022Piper SandlerInitiatesOverweight—
24 Aug 2022OppenheimerMaintainsOutperform—
21 Mar 2022OppenheimerMaintainsOutperform—
18 Mar 2022Craig-HallumMaintainsBuy—
24 Nov 2020BerenbergInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CUE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Cue Biopharma, Inc. returned −6.5% against +19.6% for the S&P 500, dividends included.

CUE vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26CUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Cue Biopharma, Inc. (CUE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
4.6×

Cheaper than 27% of US stocks

Price / book
2.9×

Cheaper than 36% of US stocks

EV / EBITDA
−1.6×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
166.7%

Higher than 95% of US stocks

Earnings growth (YoY)
1250.6%

Higher than 98% of US stocks

Gross margin
—
Operating margin
−1113.3%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1603.5%

Higher than 1% of US stocks

Return on assets
−172.7%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cue Biopharma, Inc. (CUE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cue Biopharma, Inc. has a market value of $174.2M and an enterprise value of $159.9M.

  • Revenue in the twelve months to 31 Mar 2026: $32.7M. The latest quarter grew 166.7% year on year.

  • Net income over the same four quarters: −$19.5M, a −59.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−5.58.

  • Free cash flow in the twelve months to 31 Mar 2026: −$24.6M, after $108K of capital spending.

  • Shares outstanding: 3.3M.

  • Trailing P/E: −2.9×; forward P/E: −50.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cue Biopharma, Inc. employs 29 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CUE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CUECue Biopharma, Inc.$174.2M
47
HUMAHumacyte, Inc.$173.2M
18
INDPIndaptus Therapeutics, Inc.$171.9M
24
CRBUCaribou Biosciences, Inc.$178.0M
57
MDWDMediWound Ltd.$169.4M
29
CDXSCodexis, Inc.$179.6M
68
CNTNCanton Strategic Holdings, Inc.$168.9M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cue Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CUE news & analysis

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)

PRNewsWire · 24 Aug 2026negative

Purcell & Lefkowitz LLP announced it is investigating Cue Biopharma on behalf of the company's shareholders to determine whether its directors breached their fiduciary duties in connection with recent corporate actions.

Why it matters — A shareholder investigation into potential director breaches of fiduciary duty could raise governance concerns for Cue Biopharma investors.

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 14 Aug 2026neutral

Cue Biopharma, a clinical-stage biopharmaceutical company focused on therapies for immune-mediated diseases, reported its second quarter 2026 financial results and recent business highlights on Aug. 14, 2026. The announcement covers the company's quarterly financial performance and updates on its clinical programs.

Why it matters — CUE watchers would care because the quarterly financial results and business highlights provide an update on the company's clinical-stage progress and financial position.

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

GlobeNewsWire · 3 Aug 2026positive

Cue Biopharma announced the appointment of James M. Ahlers as Chief Financial Officer and disclosed the submission of an Investigational New Drug application for its candidate CUE-221.

Why it matters — The addition of a new CFO and progression of CUE-221 into the regulatory process signal operational and pipeline advancement for the company.

FAQ

Frequently asked questions about CUE stock

What is the CUE stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Cue Biopharma, Inc. have a median 12-month price target of $115, with estimates ranging from $115 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CUE stock a buy right now?

Of the 1 analysts covering Cue Biopharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cue Biopharma, Inc. 47 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CUE?

As at 22 Aug 2026, Cue Biopharma, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will CUE stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +396.1% from the last close, and Ticker Nerd's factor model ranks Cue Biopharma, Inc. 47 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CUE stock forecast for 2030?

No analyst covering Cue Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $115 to $115 over the next 12 months.

How has CUE stock performed over the past year?

Cue Biopharma, Inc. returned -6.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cue Biopharma, Inc. do?

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics.

What is the latest news on CUE?

The most recent item we track (PRNewsWire, 24 Aug 2026): "SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)". Purcell & Lefkowitz LLP announced it is investigating Cue Biopharma on behalf of the company's shareholders to determine whether its directors breached their fiduciary duties in connection with recent corporate actions.

Company

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of injectable biologics. These engineered therapies are designed to selectively engage and modulate targeted T cells, mimicking nature's signals to expand and activate specific immune cells while restoring immune balance. The company's platform addresses serious diseases by mobilizing the patient's own immune system for precise therapeutic responses. Operating within the biotechnology industry and pharmaceuticals & biotech sector, Cue Biopharma, Inc. advances its programs through clinical development, emphasizing innovative biologics that offer potential in immunotherapy applications. Founded in 2014 and headquartered in Boston, Massachusetts, the company concentrates on creating targeted treatments that harness immune mechanisms to combat disease, positioning it as a key player in the evolving landscape of immune-oncology and related therapeutic areas.

CEO Dr. Shao-Lee Lin M.D., Ph.D. · 29 employees · United States · https://www.cuebiopharma.com